reports
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of March 2025 DENVER, April 21, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of March 31, 2025, was $21.78. This estimated NAV is not a comprehensive statement of our financial condition or results for the month March 31, 2025. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the s...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of February 2025 DENVER, March 19, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of February 28, 2025, was $22.04. This estimated NAV is not a comprehensive statement of our financial condition or results for the month February 28, 2025. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market un...
ArrowMark Financial Corp. Announces Special Distribution of $0.10 and ...
ArrowMark Financial Corp. Announces Special Distribution of $0.10 and Regular Cash Distribution of $0.45 per Share for the First Quarter 2025 DENVER, March 05, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a special cash distribution of $0.10 per share generated from excess income, and a regular cash distribution of $0.45 per share for the first quarter 2025. The total distribution of $0.55 per share will be paya...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of January 2025 DENVER, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of January 31, 2025, was $22.11. This estimated NAV is not a comprehensive statement of our financial condition or results for the month January 31, 2025. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market un...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of December 2024 DENVER, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of December 31, 2024, was $21.80. This estimated NAV is not a comprehensive statement of our financial condition or results for the month December 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market und...
Molecular Templates Announces Notice of Delisting and Failure to Satis...
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...
ArrowMark Financial Corp. Announces Q3 2024 Results and Releases Month...
ArrowMark Financial Corp. Announces Q3 2024 Results and Releases Month End Estimated Net Asset Value as of November 2024 DENVER, Dec. 17, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of November 30, 2024, was $22.24. “We are very pleased to share that the net income for Q3 2024 was $0.70 per share, well in excess of the quarterly distribution amount of $0.45 per share. Over the past five years, the Fund has consistently over-earned its quarterly distribution rate. ...
ArrowMark Financial Corp. Announces Special Distribution of $0.20 and ...
ArrowMark Financial Corp. Announces Special Distribution of $0.20 and Regular Cash Distribution of $0.45 per Share for the Fourth Quarter 2024 DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a special cash distribution of $0.20 per share generated from excess income, and a regular cash distribution of $0.45 per share for the fourth quarter 2024. The total distribution of $0.65 per share will be pay...
Molecular Templates Announces Receipt of Expected Notification of Defi...
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of October 2024 DENVER, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of October 31, 2024, was $22.02. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended October 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market ...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of September 2024 DENVER, Oct. 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of September 30, 2024, was $21.73. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended September 30, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select M...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of August 2024 DENVER, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of August 31, 2024, was $21.99. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended August 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market un...
ArrowMark Financial Corp. Announces Q2 2024 Results and Cash Distribut...
ArrowMark Financial Corp. Announces Q2 2024 Results and Cash Distribution of $0.45 per Share for the Third Quarter 2024 DENVER, Sept. 16, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial" or the “Fund”), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a cash distribution of $0.45 per share for the third quarter 2024. The distribution of $0.45 per share will be payable on September 30, 2024 to shareholders of record on September 26, 2024. “We are very pleased to announce net income...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of July 2024 DENVER, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of July 31, 2024, was $21.75. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended July 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market u...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Result...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of June 2024 DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of June 30, 2024, was $21.58. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended June 30, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of May 2024 DENVER, June 18, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of May 31, 2024, was $21.76. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended May 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the sy...
ArrowMark Financial Corp. Announces Q1 2024 Results and Cash Distribut...
ArrowMark Financial Corp. Announces Q1 2024 Results and Cash Distribution of $0.45 per Share for the Second Quarter 2024 DENVER, June 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a cash distribution of $0.45 per share for the second quarter 2024. The total distribution of $0.45 per share will be payable on June 28, 2024 to shareholders of record on June 24, 2024. “We are very pleased to announce the net inc...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) fo...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Result...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.